(Q37778984)

23 August 2017

1 reference

title

Hematopoietic SCT for the treatment of multiple sclerosis (English)

1 reference

23 August 2017

0 references

H Atkins

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

9 August 2010

1 reference

Bone Marrow Transplantation

23 August 2017

published in

1 reference

23 August 2017

volume

45

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1671-1681

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2010.168

23 August 2017

exact match

0 references

cites work

Multiple sclerosis: the environment and causation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Clinical prognostic factors in multiple sclerosis: a natural history review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Stem cell transplantation for autoimmune disorders. Preclinical experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Hematopoietic stem cell transplantation for autoimmune disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13-year followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Cladribine followed by autologous stem-cell transplantation in progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

G-CSF enhances the adhesion of encephalitogenic T cells to extracellular matrix components: a possible mechanism for exacerbation of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Collection of hematopoietic stem cells from patients with autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Transplanted bone marrow generates new neurons in human brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Autologous umbilical cord blood transfusion in very young children with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, M

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

Intense immunosuppression and stem-cell transplantation for patients with severe rheumatic autoimmune disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Course of Crohn's disease after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Autologous peripheral blood stem cell transplantation for severe multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Bone marrow transdifferentiation in brain after transplantation: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Adoptive autoimmune hyperthyroidism following allogeneic stem cell transplantation from an HLA-identical sibling with Graves' disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.168

7 January 2021

Identifiers

DOI

10.1038/BMT.2010.168

1 reference

23 August 2017

1 reference